| Literature DB >> 34918326 |
Emanuele Palomba1,2,3, Valeria Castelli1,2,3, Giulia Renisi1, Alessandra Bandera1,2,3, Andrea Lombardi1,2, Andrea Gori1,2,3.
Abstract
Influenza is an acute respiratory illness caused by the influenza A, B, and C viruses. It can occur in local outbreaks or seasonal epidemics, with possibility to spread worldwide in a pandemic when a novel strain with significant antigenic differences emerges. During the past years, several new drugs have become available, with different accessibility related to specific countries' approval. We have conducted a review of literature, analyzing the most recent data on efficacy and safety of drugs currently available to treat influenza, with a particular attention toward special populations. Efficacy and safety profile of neuraminidase inhibitors (oseltamivir, zanamivir, laninamivir, peramivir) and recently approved cap-dependent endonuclease inhibitor baloxavir marboxil are reported in literature, but still little information is available about special populations such as critically ill patients and patients with a history of chronic respiratory disease. Moreover, the emergence of strains with reduced or no susceptibility to current drugs is a matter of concern, suggesting the need of constant monitoring of viral variants. Thieme. All rights reserved.Entities:
Mesh:
Substances:
Year: 2021 PMID: 34918326 DOI: 10.1055/s-0041-1733830
Source DB: PubMed Journal: Semin Respir Crit Care Med ISSN: 1069-3424 Impact factor: 3.119